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Abstract
DNA damage checkpoints arrest cell cycle progression to facilitate DNA repair. The ability to survive genotoxic insults
depends not only on the initiation of cell cycle checkpoints but also on checkpoint maintenance. While activation of DNA
damage checkpoints has been studied extensively, molecular mechanisms involved in sustaining and ultimately inactivating
cell cycle checkpoints are largely unknown. Here, we explored feedback mechanisms that control the maintenance and
termination of checkpoint function by computationally identifying an evolutionary conserved mitotic phosphorylation
network within the DNA damage response. We demonstrate that the non-enzymatic checkpoint adaptor protein 53BP1 is
an in vivo target of the cell cycle kinases Cyclin-dependent kinase-1 and Polo-like kinase-1 (Plk1). We show that Plk1 binds
53BP1 during mitosis and that this interaction is required for proper inactivation of the DNA damage checkpoint. 53BP1
mutants that are unable to bind Plk1 fail to restart the cell cycle after ionizing radiation-mediated cell cycle arrest.
Importantly, we show that Plk1 also phosphorylates the 53BP1-binding checkpoint kinase Chk2 to inactivate its FHA domain
and inhibit its kinase activity in mammalian cells. Thus, a mitotic kinase-mediated negative feedback loop regulates the
ATM-Chk2 branch of the DNA damage signaling network by phosphorylating conserved sites in 53BP1 and Chk2 to
inactivate checkpoint signaling and control checkpoint duration.
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Introduction
Throughout the life of an organism, cellular DNA constantly
encounters chemical and radiation-induced damage. Solar and
terrestrial sources of radiation, along with the oxidative by-
products of normal metabolism, result in chemical modifications of
DNA bases and disruption of the sugar phosphate backbone.
Additional DNA lesions, including mismatched bases, and single-
or double-stranded DNA breaks, also arise during the process of
replication, which is not an error-free process [1]. To cope with
these types of genotoxic damage, cells activate powerful DNA
damage-induced cell cycle checkpoints that coordinate cell cycle
arrest with recruitment and activation of the DNA repair
machinery [2–6]. Depending on the amount of damage and the
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pathways with pathways involved in programmed cell death leads
to the elimination of irreparably damaged cells by apoptosis [7].
The global importance of these cell cycle checkpoint pathways in
maintaining genomic integrity is highlighted by the observation
that loss, mutation, or epigenetic silencing of checkpoint genes is
frequently observed in cancer [1,4]. Conversely, deletion of
checkpoint genes in non-neoplastic cells has been shown to cause
genomic instability and predisposition to transformation [1,4].
Loss of DNA damage checkpoints during early stages of
tumorigenesis not only facilitates the acquisition of additional
mutations over time [8,9] but can also be exploited in various
forms of human cancer treatment. Radiotherapy as well as many
types of anti-tumor chemotherapy are believed to preferentially kill
tumor cells by generating extensive amounts of DNA damage that
promotes cell death in checkpoint-compromised tumors, but not in
the surrounding non-neoplastic tissue where the checkpoint and
repair pathways are intact [10]. The primary cytotoxic lesion
created by therapeutic radiotherapy and most other genotoxic
treatments are DNA double-strand breaks (DSBs). It has been
estimated that a single unrepaired DSB is sufficient for cell lethality
[11].
Early events following DSB generation include local alterations
in chromatin structure, recruitment of the Mre11-Rad50-Nbs1
mediator complex to the DNA, and phosphorylation of the variant
Histone H2AX by an initial wave of activation of the checkpoint
kinase ATM [2,12–14]. Subsequent recruitment of the protein
MDC1 dramatically enhances further local activation of ATM as
part of a positive feedback loop, which in turn recruits molecules
like 53BP1 and BRCA1 [15–17]. 53BP1 facilitates DNA repair by
the error-prone non-homologous end joining (NHEJ) pathway
[18,19], while BRCA1 is important for DNA repair by the error-
free homologous recombination pathway during the S and G2
phases of the cell [20]. A major target of ATM is the effector
kinase Chk2, a critical effector kinase that functions downstream of
ATM to arrest the cell cycle after DSBs by inactivating
phosphatases of the Cdc25 family through catalytic inactivation,
nuclear exclusion, and/or proteasomal degradation [21,22]. This,
in turn, prevents Cdc25 family members from dephosphorylating
and activating Cyclin-Cdk complexes, thereby initiating G1/S and
G2/M cell cycle checkpoints.
In order for cells to survive DNA damage, it is important that
cell cycle arrest is not only initiated but also maintained for the
duration of time necessary for DNA repair. Mechanisms
governing checkpoint initiation versus maintenance appear to be
molecularly distinct. This was initially demonstrated by the
observation that interference with specific checkpoint components
can leave checkpoint initiation intact but disrupt checkpoint
maintenance, leading to premature cell cycle reentry accompanied
by death by mitotic catastrophe [7,15,23–25]. Although the
process of checkpoint termination and cell cycle reentry has not
been studied extensively, the existing data suggest that inactivation
of a checkpoint response is an active process that requires
dedicated signaling pathways, such as the Plk1 pathway [2,26,27].
Intriguingly, a number of proteins involved in terminating the
maintenance phase of a DNA damage checkpoint also play critical
roles during later mitotic events, suggesting the existence of a
positive feedback loop in which the earliest events of mitosis
involve the active silencing of the DNA damage checkpoint
through one or more mechanisms that remain unclear.
Checkpointsilencinghasbeenbest studied inthebuddingyeastS.
cerevisiae and has revealed several essential genes in this process, for
example the phosphatases Ptc2 and Ptc3, Casein kinase-I, and Srs1
[28–30]. In addition, the Polo-like kinase Cdc5 is required for
silencing checkpoint signaling, and this requirement appears to be
widely conserved, since S. cerevisiae, X. Leavis, and human cells all
depend on Plks for silencing of the S-phase or G2 checkpoints,
respectively [29,31–33]. The activity of Polo-like kinases has been
shown to be required for inactivation of the ATR-Chk1 pathway
and the Wee1 axis of checkpoint signaling. Specifically, Plk1 was
shown to create b-TrCP-binding sites on both Wee1 and the Chk1
adaptor protein Claspin, resulting in efficient ubiquitin-mediated
degradation of these target proteins [32–36]. Thus far, only
inactivation of checkpoint components of the ATR-Chk1-Wee1
signaling axes has been identified in relation to maintenance and
termination of cell cycle checkpoints. DSBs, however, primarily
trigger a checkpoint arrest through the ATM-Chk2 signaling
pathway. How, and if, the ATM-Chk2 signaling axis is actively
silenced during release of the G2 DNA damage checkpoint is
currently unclear. Here, we analyzed potential feedback mecha-
nisms responsible for terminating this process. We reasoned that
inactivation of cell cycle checkpoints after DSBs should involve at
least two arms of the ATM-Chk2 checkpoint response—both the
upstream sensor arm that maintains activation of ATM and the
downstream effector arm that functions at and below the level of
Chk2 must be silenced in order to facilitate cell cycle reentry. By
using a combination of evolutionarily constrained bioinformatics
analysis together with cell cycle–specific modifications of the highly
conserved DNA damage checkpoint signaling network, we
identified the Cdk- and Plk1-dependent phosphorylation of 53BP1
and Chk2 as critical checkpoint-inactivating events in the sensor
and effector arms of the G2/M checkpoint pathway, respectively,
that areimportantforcheckpointterminationand cell cyclereentry.
Author Summary
DNA is constantly damaged both by factors outside our
bodies (such as ultraviolet rays from sunlight) and by
factors from within (such as reactive oxygen species
produced during metabolism). DNA damage can lead to
malfunctioning of genes, and persistent DNA damage can
result in developmental disorders or the development of
cancer. To ensure proper DNA repair, cells are equipped
with an evolutionarily conserved DNA damage checkpoint,
which stops proliferation and activates DNA repair
mechanisms. Intriguingly, this DNA damage checkpoint
responds to DNA damage throughout the cell cycle,
except during mitosis. In this work, we have addressed
how cells dismantle their DNA damage checkpoint during
mitosis to allow cell division to proceed even if there is
damaged DNA present. Using the observation that kinases
phosphorylate their substrates on evolutionarily con-
served, kinase-specific sequence motifs, we have used a
combined computational and experimental approach to
predict and verify key proteins involved in mitotic
checkpoint inactivation. We show that the checkpoint
scaffold protein 53BP1 is phosphorylated by the mitotic
kinases Cdk1 and Polo-like kinase-1 (Plk1). Furthermore, we
find that Plk1 can inactivate the checkpoint kinase Chk2,
which is downstream of 53BP1. Plk1 is shown to be a key
mediator of mitotic checkpoint inactivation, as cells that
cannot activate Plk1 fail to properly dismantle the DNA
damage checkpoint during mitosis and instead show DNA
damage-induced Chk2 kinase activation. Two related
papers, published in PLoS Biology (Vidanes et al.,
doi:10.1371/journal.pbio.1000286) and PLoS Genetics (Don-
nianni et al., doi:10.1371/journal.pgen.1000763), similarly
investigate the phenomenon of DNA damage checkpoint
silencing.
Silencing the ATM-Chk2 G2/M Checkpoint
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The ATM-Chk2 Pathway Is Silenced in Mitosis
To identify potential feedback and control mechanisms that
extinguish the ATM-Chk2 signaling axis of the G2/M DNA
damage checkpoint, we initially investigated whether we could
observe silencing of this network under particular cell states or
conditions. Molecular targets that are known to be inactivated in
other G2/M cell cycle checkpoint control pathways, i.e. the ATR/
Chk1 pathway, include Wee1 and Claspin [32–36] and inactiva-
tion of these components results in a shutdown of this checkpoint
signaling pathway following mitotic entry. If the ATM-Chk2
pathway was also inactivated upon mitotic entry, clear differences
would be expected when interphase cells are compared to mitotic
cells following irradiation. To examine this, U2OS cells were
exposed to 10 Gy of ionizing radiation (IR), and activation of the
upstream checkpoint kinase ATM and the downstream effector
kinase Chk2 were examined by immunoblotting (Figure 1A, B). In
order to investigate whether mitotic cells remained in mitosis upon
irradiation in our experimental set-up, we used two mitotic
markers, MPM-2 immunoreactivity and the presence of Plk1
(Figure 1B). The monoclonal MPM-2 antibody was originally
cloned on the basis of its ability to specifically recognize mitotic but
not interphase cells [37]. MPM-2 recognizes multiple mitosis-
specific phospho-proteins, and its reactivity thus indicates the
abundance of mitotic cells. Plk1, on the other hand, is highly
expressed in G2 and M-phase of the cell cycle and is degraded
during mitotic exit [38]. Importantly, we observed that irradiation
of mitotic cells did not lead to mitotic exit, as judged by the
persistently elevated levels of Plk1 and MPM-2 immunoreactivity
(Figure 1B). As shown in Figure 1A, in response to IR, ATM was
efficiently activated regardless of cell cycle phase. We observed
both rapid phosphorylation of Chk2 on Thr-68, a known ATM
phosphorylation site, and enhanced Chk2 kinase activity
(Figure 1B,C), after irradiation of interphase cells. However,
irradiation of mitotic cells failed to result in phosphorylation of
Chk2 on Thr-68, and the DNA damage-induced increase in Chk2
kinase activity was severely impaired (Figure 1B,C). This suggests
that ATM may not efficiently form complexes with some of its
critical downstream substrates such as Chk2 in response to DNA
damage during mitosis, resulting in a failure to activate Chk2 and
Chk2-dependent effector pathways required for cell cycle arrest.
This hypothesis is in line with previous reports in which c-
irradiation or treatment with topoisomerase inhibitors were shown
not to interfere with progression of cells already in mitosis [39,40],
indicating that DNA damage checkpoint pathways are function-
ally inactivated during mitosis.
Reconstructing a Phosphorylation Network of DNA
Damage Proteins
To elucidate potential molecular mechanisms responsible for
checkpoint silencing of the ATM-Chk2 axis in mitosis, we used a
supervised computational network/bioinformatics approach. First,
we identified a set of core proteins involved in the human G2/M
checkpoint and mapped known in vivo phosphorylation sites
[41–44] onto them (Figure 2A,B and Table S1). Next, this set of
phospho-proteins was used to query for conservation of the
phosphorylation sites, defined by five residues N-terminal and five
Figure 1. Inactivation of the ATM-Chk2 checkpoint signaling pathway upon mitotic entry. (A) Asynchronous U2OS cells were untreated
(‘‘interphase’’) or treated with nocodazole (‘‘mitosis’’) for 16 h and collected by shake-off. Where indicated, cells were irradiated with 10 Gy and
harvested 30 min later. Whole cell lysates were immunoblotted for total and Ser-1981 phosphorylated ATM. (B) Cell lysates prepared as in panel A
were immunoblotted with the indicated total and phospho-specific antibodies. (C) Lysates as in panel B were analyzed for Chk2 kinase activity using
an IP/kinase assay. Error bars indicate SEM.
doi:10.1371/journal.pbio.1000287.g001
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protein orthologs across eleven vertebrate genomes. We computed
the conservation as the mean percentage of conserved residues
within this eleven-mer site window across these vertebrate
genomes. The kinases responsible for generating these phosphor-
ylation sites were identified using data from PhosphoELM [42] or
predicted using the NetworKIN algorithm [45–47]. In addition,
we used Scansite [48] to identify potential docking sites for the
Plk1 Polo-Box Domain (PBD) [44,49,50] within the network. As
would be expected, we observed that many of the checkpoint
proteins contained highly conserved ATM/ATR sites (Figure 2A,B
and Table S1). Importantly, we also identified highly conserved
phosphorylation sites for Cdk1/2 and Plk1 kinases distributed
relatively equally on proteins throughout the network, indepen-
dently of whether the proteins were classified into ‘‘checkpoint’’ or
‘‘cell cycle’’ modules. No potential molecular targets could be
uniquely pinpointed by looking only at the putative kinase-
substrate level; thus the mitotic/DNA damage phosphorylation
network seems to be robust in the sense that they are highly
connected via relatively few but pleotropic kinases. However,
when we searched for PBD binding sites, only a few network
components appeared (Figure 2B) including the previously
validated Plk1 binding target Cyclin B [51]. In addition, several
components of the checkpoint signaling pathway appeared as
putative Plk1 PBD-binding targets, notably MDC1 and 53BP1.
Surprisingly, these two proteins belong to the non-enzymatic
checkpoint adaptor family of proteins that function in the ATM-
Chk2 pathway [16,52–57].
53BP1 Is a Target for Cdk1 and Plk1 and Fails to Form
Foci after DNA Damage in Mitosis
We focused on 53BP1, since our analysis predicted eight highly
conserved Cdk1/2 phosphorylation sites as well as three sites with
lower conservation. Importantly, five of the highly conserved
Cdk1/2 phosphorylation sites constitute putative PBD binding
sites. We have previously shown that 53BP1 is a target of Cdk1-
Cyclin B during mitosis [45]. Here, we aimed to investigate the
functional implications of these phosphorylation events and again
employed the MPM-2 antibody, which recognizes proteins that
are phosphorylated on Cdk1/2 consensus motifs [37,58,59]. By
immunoprecipitating 53BP1 from mitotic cell extracts, we
observed clear immunoreactivity with the MPM-2 antibody, in
stark contrast to 53BP1 immunoprecipitated from interphase cells
(Figure 3A). These results were further strengthened by in vitro
kinase assays, in which recombinant Cdk1-Cyclin B, but not
Cdk2-CyclinA, efficiently phosphorylated 53BP1 (Figure 3B).
If 53BP1 is a critical target for checkpoint silencing by mitotic
kinases, then the function of 53BP1 should be altered during
mitosis. We therefore investigated the co-localization of 53BP1
and DNA damage–induced foci at different cell cycle phases. Few
c-H2AX foci were observed in untreated cells, while their number
increased dramatically after 3Gy of IR (Figure 3C, Figure S1B left
panel). Similar behavior was observed for 53BP1 (Figure 3C,
Figure S1B left panel). In interphase cells, approximately 70% of
c-H2AX foci contained 53BP1 (Figure 3C, Figure S1B middle
panel). However, when nuclear foci of 53BP1 were present, they
always overlapped with c-H2AX in both untreated as well as in
IR-treated cells during interphase (Figure 3C, Figure S1B right
panel). In contrast, in mitotic cells there were essentially no distinct
53BP1 foci that were observed regardless of the presence or
absence of irradiation, and instead 53BP1 appeared to be largely
excluded from chromatin. Hence, in mitosis no overlap was
detected between the localization of c-H2AX foci and 53BP1,
showing that the function of 53BP1 in the DNA damage response
(DDR) is indeed modified during mitosis, either directly or
indirectly (Figure 3C).
In addition to changes in IR-induced localization of 53BP1, we
also observed that the protein levels of 53BP1 rapidly declined as
cells passed synchronously through the cell cycle (Figure 3D).
However, the decrease in 53BP1 protein levels occurred only at
late stages of mitosis or cell cycle reentry, after the destruction of
Cyclin B, and thus may not have a prominent role in G2
checkpoint inactivation.
The NetworKIN algorithm, in addition to predicting 53BP1 as
a substrate for Cdk1, also predicted putative Plk1 phosphorylation
and PBD binding-site(s) in 53BP1 (Figure 2B). To investigate the
functional roles of these sites, we immunoprecipitated endogenous
53BP1 from interphase or mitotic U2OS cells and examined the
immunoprecipitates for co-association of Plk1 (Figure 4C). Where-
as 53BP1 and Plk1 did not co-immunoprecipitate during
interphase, a significant amount of Plk1 interacted with 53BP1
during mitosis (Figure 4C and Figure S1A). In addition to binding
to 53BP1, Plk1 was able to efficiently phosphorylate 53BP1 in vitro
(Figure 4D). To further identify the site(s) in 53BP1 that interact
with Plk1, mutational analysis was performed (a selection of
phosphorylation site mutants is indicated in Figure 4A,B). Lysates
of interphase or mitotic U2OS cells stably expressing wt or mutant
forms of GFP-tagged murine-53BP1 were incubated with the
recombinant GST-tagged PBD from Plk1 (residues 363–562).
Mitotic forms of 53BP1 show reduced migration on low
percentage SDS-page gels, resulting in multiple bands in mitotic
lysates from cells expressing endogenous as well as GFP-tagged
53BP1 (Figure 4E). As expected, wt-GFP-m53BP1 was efficiently
pulled down by GST-PBD from mitotic lysates, but not from
interphase lysates (Figure 4E). Like wt-GFP-m53BP1, both the
GFP-m53BP1-1103A and mGFP-m53BP1-1620A mutants (cor-
responding to residues 1114 and 1635 in human 53BP1) efficiently
bound to the Plk1 PBD (Figure 4F and unpublished data). A third
predicted PBD binding site within 53BP1 (S380) resides in a
Figure 2. Conservation of mapped phosphorylation sites in the DNA damage signaling network. (A) Example of a conserved ATM/ATR
phosphorylation motif [ST]Q in H2AX. Left: the human H2AX sequence, in which the mapped phosphorylation site was identified, was aligned with
orthologous sequences from the indicated genomes. No orthologues for cow, chicken, zebrafish, or pufferfish are present in the Ensembl database.
Analysis of the 25/+5 region surrounding Ser139 (green box) showed conservation of 100% (M. mulatta; C. familiaris), 87.5% (M. musculus; R.
norveticus), 75% (O. anatinus), and 62.5% (X. tropicalis), leading to a mean conservation of 88.2%. Right: the site is indicated by a vertical column
composed of central and flanking bars. The height of the central bar indicates the extent of conservation of the central phospho-acceptor residue
among the identified orthologues (red, 100%). The height of the flanking bars indicates conservation within the 11 amino acid region surrounding
the phosphosite (grey, 88.2%). (B) Phosphorylation network and evolutionary analysis for components of the DNA damage checkpoint signaling
pathways. Each protein in the reconstructed network is shown as a grey box containing columns corresponding to each previously identified in vivo
phosphorylation sites. The height of the bars in each column indicates the evolutionary conservation of the site amongst the vertebrates, as shown in
panel A and tabulated in Table S1. The NetworKIN algorithm was used to reconstruct a network of kinases involved in these phosphorylation events,
and predictions for Cyclin-dependent kinases (yellow), ATM/ATR (red), CHK1/2 (orange), and Polo-like kinase-1 (blue) are displayed. Sites known tob e
phosphorylated by other or unknown kinases are shown in dark and light grey, respectively. Polo-box binding sites are shown in green. Lines indicate
established signaling interactions.
doi:10.1371/journal.pbio.1000287.g002
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been shown to be phosphorylated in vivo). A 53BP1 mutant
lacking this cluster of potential PBD binding sites (GFP-m53BP1
D196–439) did not interact with the PBD of Plk1 (Figure 4F).
Importantly, the single highly conserved and predicted PBD-
binding site that is found phosphorylated in vivo, S380
(corresponding to the S376 in murine 53BP1), appeared to be
essential for the mitotic interaction between 53BP1 and Plk1, as
the GFP-m53BP1-376A mutant could not be precipitated from
mitotic lysates with recombinant PBD (Figure 4F). Furthermore,
re-analysis of in vivo phosphorylation sites from mitotic Plk1 PBD
pull-downs revealed the presence of phospho-S380 peptides from
endogenous 53BP1 [44]. Combined, these results indicate that
S380 is a critical site amongst the predicted CDK1/2 sites that is
required for stable binding to Plk1. Although mass-spectrometry-
based phospho-proteomics previously identified S380 as an in vivo
phosphorylation site [41,44], the dynamics of S380 phosphoryla-
tion during different phases of the cell cycle are unclear. In
agreement with a model in which S380 is phosphorylated during
mitosis, we could only observe S380 phosphorylation of 53BP1 in
mitotically arrested cells, but not in interphase cells using a
phospho-specific antibody raised against this site (Figure 4G).
Furthermore, detailed analysis of phosphorylation during the cell
cycle revealed intense phosphorylation of S380 when synchronized
cells entered mitosis (Figure 3D), consistent with this site being a
Cdk1 target. Finally, treatment of mitotic cells with the Cdk1
inhibitor roscovitine eliminated S380 phospho-reactivity
(Figure 4G).
53BP1 Is Not Involved in Normal Mitotic Progression
Although the identification of mitotic phosphorylation sites in
DNA damage checkpoint proteins can elucidate potential
feedback targets within the checkpoint networks, it is conceivable
that mitotically phosphorylated checkpoint proteins could also
possess alternative cellular functions. Mitotic phosphorylation of
such proteins could, for example, be important for the regulation
of normal mitotic progression, rather than facilitating feedback
control during an exogenous G2 DNA damage checkpoint
response. To investigate a possible role for 53BP1 during an
unperturbed mitosis, we stably infected U2OS or MCF7 cell lines
with 53BP1 RNAi hairpins and examined these cells for possible
defects in mitotic progression (Figure 5). We used two independent
hairpins that significantly decreased 53BP1 levels in both U2OS
and MCF7 cell lines (Figure 5A). To select for a functional 53BP1
knockdown, MCF7 cell lines were treated with the MDM2
inhibitor Nutlin-3 [60]. Nutlin-3 treatment leads to a cell cycle
arrest that depends on p53 as well as 53BP1 [60,61]. As expected
and reported previously, knockdown of 53BP1 significantly
increased mitotic indices, the number of cells in S-phase, as well
as the size and number of proliferating colonies following Nutlin-3
treatment (Figure 5B,C,D and unpublished data) in the 53BP1
knockdown cells. Although the increases in M- and S-phase
content after Nutlin treatment in 53BP1 knockdown cells is minor,
the increase in colony formation suggests that this effect is
meaningful. A functional 53BP1 knockdown was also evidenced by
a small but highly reproducible increase in mitotic content after
low dose (2 and 3 Gy) ionizing radiation (unpublished data). In
contrast, no differences in mitotic indices were observed in the
untreated cell population, indicating that loss of 53BP1 does not
interfere with normal mitotic progression. Likewise, paclitaxel
treatment resulted in similar increases in the percentages of mitotic
cells in control and 53BP1-depleted lines, suggesting that 53BP1 is
not required for normal functioning of the spindle assembly
checkpoint (Figure 5E).
Mitotic Phosphorylation of 53BP1 Contributes to DNA
Damage Checkpoint Exit
Our finding that 53BP1 is not involved in spindle checkpoint
functioning allowed us to use microtubule poisons to trap cells in
mitosis after checkpoint escape, even in cells with modulated
53BP1 expression levels. In these experiments, if the observed
mitotic phosphorylation of 53BP1 is important for attenuating the
DNA damage checkpoint, one would expect to observe altered
kinetics of G2-M transition when phosphorylation site mutants of
GFP-m53BP1 are expressed, especially after cells are treated with
genotoxic compounds. To first assess how phosphorylation by
mitotic kinases alters the function of checkpoint components such
as 53BP1, we utilized genetic and chemical inhibition of Plk1.
Previously, a role for Plk1 in checkpoint silencing was identified by
using siRNA technology [32–36]. Although clear differences in cell
cycle reentry were observed after silencing Plk1 expression, a
limitation of these RNAi experiments is that they cannot
distinguish between a requirement for the mere presence of Plk1
in checkpoint recovery or for the enzymatic activity of Plk1 during
this process. We therefore wished to confirm these results using the
temporally controlled chemical inhibition of Plk1 [62]. As
previously reported, chemical inhibition of Plk1 using BI-2536
led to spindle checkpoint activation and a concomitant mitotic
arrest [63] with kinetics similar to those seen in nocodazole- or
paclitaxel-treated cells (Figure 6A and unpublished data). More-
over, when the G2 DNA damage checkpoint was activated in
U2OS cells by c-irradiation, and the checkpoint then abrogated
by treatment of the damaged cells with the ATM/ATR inhibitor
caffeine, the cells rapidly entered mitosis, where they could be
trapped in the presence of paclitaxel (Figure 6B). In contrast, cells
treated with the Plk1 inhibitor were unable to enter mitosis and
remained in G2, clearly indicating that Plk1 kinase activity, rather
than physical presence of Plk1 per se, is required for cell cycle
reentry after a DNA damage checkpoint arrest when the upstream
checkpoint signaling pathways are silenced with caffeine. This
effect does not appear to result from DNA damage induced by
Plk1 inhibition, as was previously suggested [64], since Plk1
inhibition did not initiate DNA damage-induced foci (Figure S1C).
In addition to caffeine-induced checkpoint abrogation, we could
show that Plk1 activity was equally important for spontaneous
checkpoint recovery (Figure 6C). In response to low dose IR
Figure 3. Cell cycle–dependent changes in post-translational modification and localization of 53BP1. (A) Asynchronous U2OS cells were
left untreated or treated with paclitaxel for 16 h and collected by shake-off. Cell lysates were used for 53BP1 immunoprecipitations and analyzed by
Western blotting. Ten percent of input as well as 53BP1 immunoprecipitations were analyzed using anti-MPM-2 and anti-53BP1 antibodies. (B)
Interphase U2OS cells were lysed and processed for 53BP1 immunoprecipitations. 53BP1 immunoprecipitations were subsequently used as in vitro
substrates for either Cdk1-Cyclin B or Cdk2-Cyclin A. Phosphorylation of 53BP1 was analyzed by SDS-PAGE/autoradiography. (C) Asynchronously
growing U2OS cells were left untreated or irradiated with 5 Gy ionizing radiation. Thirty minutes after irradiation, cells were fixed, permeabilized, and
stained for 53BP1 and c-H2AX. Magnifications represent examples of mitotic or interphase cells before or after irradiation. (D) U2OS were
synchronized using a double thymidine block. At indicated time points after release, cells or cell lysates were analyzed by flow cytometry or SDS-
PAGE/immunoblotting as indicated. Left panel: at each time point, 10,000 events were analyzed for phospho-Histone H3 staining by flow cytometry.
Right panel: lysates prepared at indicated time points were analyzed for expression of 53BP1, phosphoSer380-53BP1, b-actin, and Cyclin B.
doi:10.1371/journal.pbio.1000287.g003
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during which time cumulative mitotic entry is significantly lower
(Figure 6C). When cells were treated with the Plk1 inhibitor
following low-dose DNA damage checkpoint activation, similarly
low mitotic indices were observed. However, unlike control cells in
which the mitotic index had recovered to approximately 80% of
the levels seen in unirradiated cells by 16 h after 2 Gy ionizing
radiation, cells that were irradiated and treated with the synthetic
Plk1 inhibitor maintained persistently low mitotic indices
(Figure 6C). These results confirm a specific role for the kinase
activity of Plk1 in spontaneous cell cycle reentry after a G2
DNA damage checkpoint arrest, as well as the requirement for
Plk1 for normal mitotic progression beyond metaphase
[31,32,34,35,65,66].
Next, to explore whether the interaction of 53BP1 with Plk1 was
important for the DNA damage recovery phenotype, we irradiated
U2OS cells, expressing GFP-tagged wt-m53BP1 or a GFP-53BP1
mutant that was unable to bind Plk1 (Figure 6D), and monitored
persistence of DNA damage checkpoint activity 24 h later by
quantitatively measuring levels of H2AX phosphorylation by flow
cytometry. As shown in Figure 6D, both the control untransfected
cells and the cells expressing wt-53BP1 showed only background
levels of c-H2AX staining by this time after irradiation. In
contrast, 24 h after irradiation cells expressing the Plk1-binding
mutant GFP-m53BP1-S376A showed persistently increased c-
H2AX-positivity (Figure 6D). To assess the effects of such altered
checkpoint activation on cell cycle progression, a parallel set of
studies was performed in the absence (Figure 6E) or presence of
low-dose IR (Figure 6F), and mitotic entry quantified by
measuring phospho-Histone H3 staining in the presence of
paclitaxel to trap all cells exiting G2 in mitosis. As shown in
Figure 6E, in the absence of DNA damage cells, expressing the
S376A-m53BP1 mutant showed no reduction in mitotic entry—if
anything, the percentage of pH3-positive cells was slightly
increased in m53BP1 mutant-expressing cells. In contrast, cells
expressing S376A-m53BP1 were delayed in mitotic entry after
irradiation with low-dose IR compared to either untransfected
cells (unpublished data) or cells expressing wt-m53BP1 (Figure 6F),
in agreement with the observed increase in checkpoint activity.
These results strongly suggest that mitotic regulation of 53BP1 by
Plk1 modulates DNA damage checkpoint activity to control
checkpoint recovery.
It was previously suggested that 53BP1 functions as a molecular
platform/scaffold for the efficient recruitment, phosphorylation,
and activation of several checkpoint components including p53,
BRCA1, and Chk2 [57,67–70]. Chk2 is a Ser/Thr kinase that
possesses an SQ/TQ-rich N-terminus, an N-terminal phospho-
peptide-binding Forkhead-Associated (FHA) domain that is crucial
for Chk2 activation, and a C-terminal kinase domain. Specifically,
53BP1 was shown to be required for Chk2 activation in response
to DNA damage, as Chk2 activation was shown to be significantly
impaired in 53BP1 null cells and in cells where 53BP1 was
depleted by RNAi [57,69,70], particularly when exposed to low
doses of IR [70], or when signaling through the MDC1 branch of
the DNA damage signaling pathway is suppressed [69,71,72].
Interestingly, the inability of Chk2 to be activated during mitosis
(Figure 1B,C) strongly correlates with the absence of 53BP1 from
DNA damage–induced foci in irradiated mitotic cells (Figure 3C)
and with the mitotic phosphorylation of 53BP1 on Ser-376 to
generate a Plk1 PBD binding site. These data suggest that 53BP1
may function as a docking platform where Plk1 and Chk2 can
bind and possibly interact.
Plk1 Can Disable Chk2 by Phosphorylating the FHA
Domain
To test the hypothesis that Plk1 kinase activity could inhibit
Chk2 as part of the mechanism of checkpoint inactivation, we first
examined whether the activity of Plk1 could be responsible for the
inability of DNA damage to activate Chk2 during mitosis
(Figure 1B,C). In these experiments, U2OS cells were treated
with nocodazole in the absence or presence of the Plk1 inhibitor BI
2536, and mitotic cells then isolated and irradiated with 5 Gy of
ionizing radiation. Chk2 activity was measured 1 h after
irradiation using an immunoprecipitation/in vitro kinase assay
(Figure 7A). No increase in Chk2 kinase activity was observed in
the irradiated mitotic cells compared to the unirradiated mitotic
cells, as expected. If the mitotic cells were treated with the Plk1
inhibitor, however, a marked elevation of Chk2 kinase activity was
seen after DNA damage, consistent with a model where Plk1
kinase activity suppresses Chk2 activity during mitosis. We next
examined whether Chk2 could be a direct substrate of Plk1. As
shown in Figure 7B, incubation of full-length Chk2 with Plk1 in
the presence of [
32P]-c-ATP resulted in significant Chk2
phosphorylation, as visualized by
32P incorporation and a clear
phosphorylation-induced mobility shift (Figure 7B). In order to
examine whether these effects could be recapitulated in vivo
during checkpoint recovery, we irradiated U2OS cells expressing
FLAG-tagged Chk2 in the absence or presence of Plk1 inhibitor
(Figure 7C). Following checkpoint inactivation using caffeine,
FLAG-Chk2 was immunoprecipitated and analyzed by SDS-
PAGE. Cells treated with the Plk1 inhibitor showed a markedly
faster migrating form of Chk2, confirming that the Plk1-dependent
modification that was observed in vitro also occurs in vivo.
Surprisingly, in vitro phosphorylation of Chk2 by Plk1 had only a
minor effect on the ability of the Chk2 kinase domain to
phosphorylate an optimal peptide substrate (Figure 7D). In
Figure 4. Interaction of 53BP1 and Plk1. (A) Putative Polo-like kinase-1 binding sites within 53BP1 are indicated, along with site conservation
across M. musculus and X. tropicalis. Asterisks mark residues that were found to be phosphorylated in vivo. (B) Schematic representation of 53BP1
protein organization along with location of putative Plk1-binding sites. Lower part: a selection of GFP-tagged murine 53BP1 constructs used in this
study. Asterisks mark residues that were mutated to Ala. (C) U2OS cells were left untreated or treated with paclitaxel for 16 h, and mitotic cells were
isolated by mitotic shake-off. 53BP1 was immunoprecipitated, and lysates (‘‘input 10%’’) or immunoprecipitations (‘‘53BP1 IP’’) were analyzed by
Western blotting for 53BP1, Plk1, and b-actin. (D) 53BP1 was immunoprecipitated from interphase lysates and used as a substrate for Cdk1-Cyclin B or
Plk1 kinase (Plk1 T210D). Incorporation of [
32P]-c-ATP was visualized by SDS-PAGE/autoradiography. (E) Interphase or mitotic lysates of U2OS cells
and U2OS cells, stably expressing GFP-tagged wt-m53BP1, were incubated with immobilized GST-Plk1-PBD. Endogenous 53BP1 and GFP-tagged
m53BP1 associated with GST-Plk1-PBD were analyzed by immunoblotting using anti-GFP and anti-53BP1 antibodies. ‘‘I’’ indicates 10% input for
immunoprecipitations. ‘‘PBD’’ indicates pull-downs using the GST-Plk1 Polo-box domain. (F) Mitotic lysates of U2OS cell lines, stably expressing the
indicated GFP-tagged m53BP1 constructs, were incubated with immobilized GST-Plk1-PBD. The inputs (‘‘lysate’’) and GST-Plk1-PBD associated 53BP1
were analyzed by immunoblotting using anti-GFP antibody. Equal loading of lysates and GST-Plk1 (a.a. 356–603) is indicated by coomassie staining.
The lower graph indicates quantification of the 53BP1 signal on the Western blot. Signal was corrected for local background and input levels were set
to 100%. (G) U2OS cells were left untreated of treated with nocodazole for 16 h. Nocodazole-treated mitotic cells were isolated by shake-off and, if
indicated, subsequently treated with the Cdk1-inhibitor roscovitine for 30 min. Cell lysates were analyzed using anti-53BP1, anti-phospho-S376-
53BP1, or anti-b-actin antibodies.
doi:10.1371/journal.pbio.1000287.g004
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Chk2 by Plk1 completely abrogated the ability of the FHA domain
to bind to its phosphopeptide ligands (Figure 7E). Since the FHA
domain is known to be critical for DNA damage–induced
phosphorylation, oligomerization, and activation of Chk2 in vivo
[73–76], our results indicate that loss of Chk2 activation and
function in cells during both mitosis and recovery from a DNA
damage checkpoint likely involves contributions from both Plk1
binding to 53BP1 and direct phosphorylation-induced inactivation
of the Chk2 FHA domain. To further examine this, the Plk1
phosphorylation sites within the FHA domain of Chk2 were
mapped using nano-liquid chromatography and mass spectrom-
etry (Figure 7F and Figure S2A–C), revealing three sites, Ser-164,
Thr-205, and Ser-210, that are both evolutionarily conserved and
match the optimal phosphorylation motif for Plk1 ([77]; Alexander
and Yaffe, manuscript in preparation). Mapping of these sites onto
the X-ray crystal structures of the Chk2 FHA:phosphopeptide
complex [78] and the recently solved structure of the near-full-
length Chk2 dimer (Figure 7G) [79] reveals that one of these sites,
Ser-164, is in close proximity to the phosphopeptide-binding site,
with its phosphorylation likely to disrupt ligand binding through
electrostatic repulsion of the ligand phosphothreonine residue
(Figure 7G right panel). Both Thr-205 and Ser-210 lie at the
interface between the two monomers in the dimeric Chk2
structure that is believed to represent the early stages in the
Chk2 activation process [79]. Phosphorylation of these residues
would be expected to disrupt both the dimeric FHA:FHA domain
interaction as well as the interaction between the FHA domain of
one monomer with the kinase-FHA linker of the other (Figure 7G
left panel). It is not technically possible to directly assay Plk1-
dependent alterations in phosphopeptide-binding capacity of the
Chk2 FHA domain within cells expressing wild-type or mutant
53BP1. Therefore, to determine if phosphorylation of the FHA
domain by Plk1 contributes to the observed Plk1 dependence of
checkpoint silencing, we tested whether mutation of the identified
phosphorylation sites affected the ability of cells to recover from a
DNA damage checkpoint arrest. In these experiments, cells were
transfected with wild-type or mutant forms of Chk2 in which each
of the phosphorylation sites was replaced by Ala, along with an
IRES-driven GFP (Figure 7H). Expression of wild-type or mutant
forms of Chk2 did not result in altered cell cycle distributions
under untreated conditions (Figure 7H). In marked contrast,
mutation of Ser-164, Thr-205, or Ser-210 to a non-phosphor-
ylatable residue was found to clearly impair checkpoint recovery,
as judged by a significant decrease in cumulative mitotic entry at
24 h after irradiation (Figure 7I), with mutation of Ser-164
showing the greatest effect. These results show that Chk2
phosphorylation by Plk1 inhibits the function of the FHA domain
and that these phosphorylation events contribute to inactivation of
the DNA damage checkpoint during mitosis and checkpoint
recovery.
Discussion
In response to genotoxic injury, cells activate a network of DNA
damage signaling pathways involving the upstream serine/
threonine kinases ATM and ATR and the downstream kinases
Chk1, Chk2, and MK2 to induce G1, S, and G2 cell cycle arrest,
recruit repair machinery to the sites of damage, and target
irreversibly damaged cells for apoptosis [4,80]. ATR and its
downstream effector kinase Chk1 are essential genes that respond
primarily to single-strand DNA lesions and bulky base modifica-
tions. In contrast, the ATM-Chk2 signaling pathway, which is
activated by DSBs (considered to be the most lethal type of DNA
damage), is composed of nonessential genes. Their importance,
however, is highlighted by the observation that interference with
ATM and Chk2 function severely impairs the checkpoint response
to IR and other DSB-inducing lesions, and mutation of the genes
encoding for ATM and Chk2 results in the cancer-prone Ataxia-
Telangiectasia syndrome, and familial breast and prostate cancer,
respectively [81–87]. Following DNA repair, cells must extinguish
the DNA damage signal to allow the cells to reenter the cell cycle,
but the mechanisms through which this occurs, particularly with
respect to the ATM-Chk2 pathway, are poorly understood.
Since DNA damage checkpoints respond to as little as a single
DNA DSB in model systems [25,26], it has long been assumed that
human cells also maintain the G2/M checkpoint until all of the
breaks are repaired. Recent evidence, however, shows that the G2
checkpoint in immortalized human cells in culture displays a
defined threshold of approximately 10–20 DSBs [23]. Limited
checkpoint control was not only apparent in response to IR doses
that cause very few DNA DSBs, cells that had also repaired more
extensive amounts of DNA damage also showed checkpoint
release when fewer than 10–20 DSBs were left unrepaired [23].
Although the fate of cells that continue proliferating in the
presence of unrepaired DNA breaks is unclear, and the identity of
the rate-limiting DNA damage checkpoint components has yet to
be uncovered, a picture is emerging in which certain cues are
capable of overriding the DNA damage checkpoint machinery. G2
checkpoint escape in the presence of unrepaired DNA damage
may be particularly common during the evolution of cancer cells
[2,4,5,8,9], reinforcing the need to better understand this process
in molecular detail.
Recently, a pathway comprising Aurora A, Bora, and Plk1 was
shown to control inactivation of the G2 DNA damage machinery
[65,88]. Although several targets of Plk1 within or downstream
from the ATR-Chk1 pathway that are involved in DNA damage
checkpoint silencing have been described, no target within the
ATM-Chk2 pathway has been identified thus far [32–36]. Here,
we have used a combined bioinformatics and biochemical
approach to identify targets of mitotic kinases within the DNA
damage checkpoint. We show that the 53BP1 checkpoint protein
interacts with Plk1 and is phosphorylated by Cdk1/Cyclin B and
Plk1. In addition, we show that expression of a 53BP1 mutant that
Figure 5. Cell cycle analysis of 53BP1-depleted cells. (A) MCF7 and U2OS cells stably expressing pRS-53BP1#1 or pRS-53BP1#2 shRNA hairpins
or pRS control vectors were analyzed by SDS-PAGE and immunoblotting for 53BP1. b-actin serves as a loading control. (B) Cell cycle analysis of MCF7
(upper panels) or MCF7-pRS-53BP1#1 (lower panels) after incubation with 4 uM Nutlin-3 for 7 d. DNA content (middle panels) and phospho-Histone
H3 levels (right panels) were assessed by flow cytometry. Percentages of S-phase cells (middle) and phospho-Histone H3 positive cells (right) are
indicated. (C) MCF7-pRS, MCF7-pRS-53BP1#1, and MCF7-pRS-53BP1#2 cells were treated as in panel B. The percentages of phospho-Histone H3-
positive cells from three independent experiments were measured. Mean values and SEM are shown. p values obtained with the unpaired t test are
indicated (*p,0.05, ** p,0.001). (D) Cells were treated as in panel B, plated at low density, and numbers of surviving colonies were measured for
three independent experiments. Mean numbers of colonies per microscopy field and SEM are show. Statistical analysis of colony number differences
is indicated (***p,0.001). (E) MCF7-pRS control cells, MCF7-pRS-53BP1#1, and MCF7-pRS-53BP1#2 cells, or U2OS-pRS control, U2OS-pRS-53BP1#1,
and U2OS-pRS-53BP1#2 cells were left untreated or treated with paclitaxel for 16 h. Cells were harvested and analyzed for the percentage of
phospho-Histone H3-positive cells using FACS. Mean values and SEM from three independent experiments are shown.
doi:10.1371/journal.pbio.1000287.g005
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PLoS Biology | www.plosbiology.org 11 January 2010 | Volume 8 | Issue 1 | e1000287Figure 6. Phosphorylation of 53BP1 controls DNA damage checkpoint release. (A) U2OS cells were treated for indicated time periods with
DMSO, paclitaxel, or the Plk1 inhibitor BI 2536. Cells were stained using anti-phospho-Histone H3 and analyzed by FACS. Mean values and SEM from
three experiments are indicated. (B) U2OS cells were left untreated or treated with 10 Gy ionizing irradiation (IR). Twelve hours after irradiation
(indicated as t=0 h), cells were left untreated or incubated with or without caffeine in the absence or presence of the Plk1 inhibitor BI 2536 for 3 or
6 h in the presence of paclitaxel to visualize cumulative mitotic entry. Phospho-Histone H3 content was measured by FACS. (C) U2OS cells were left
untreated or treated with 2 Gy ionizing irradiation (IR). Thirty minutes after irradiation, cells were incubated with paclitaxel in the absence (white bars)
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53BP1 was previously identified as a non-enzymatic DNA damage
checkpoint mediator protein that is recruited to sites of DNA
damage through protein-protein interactions, oligomerization, and
binding to methylated histones [89–94]. Although the recruitment
of 53BP1 to sites of DNA damage has been studied intensively, the
exact functions of 53BP1 are only beginning to emerge. 53BP1
was recently shown to regulate DNA repair as a component of the
NHEJ network [18,19,95]. In addition, 53BP1 regulates check-
point responses by interacting with a range of downstream
checkpoint components, including Chk2 and p53 [57,61,69,70].
Our results strengthen a role for 53BP1 as a checkpoint
regulator and indicate that 53BP1 functions as a binding platform
for Plk1 during the checkpoint recovery process. This suggests a
model in which 53BP1 might mediate a direct interaction between
Plk1 and the 53BP1-binding protein Chk2. We suggest that
mitotic Cdk1 phosphorylation of 53BP1 and subsequent interac-
tion of Plk1 and 53BP1 may function to bring Plk1 and the 53BP1-
interacting protein Chk2 in close proximity (Figure 8, step 1).
Subsequent direct phosphorylation of Chk2 by Plk1 (Figure 8, step
2) leads to impaired Chk2 phosphopeptide-binding ability by its
FHA domain, which is required for continued Chk2 activation
and function in cell cycle arrest (Figure 8, step 3). Our results fit
well with previous observations in fission yeast in which a
prolonged DNA damage–induced checkpoint arrest was observed
when Cdk phosphorylation site mutants of the 53BP1 homologue
Crb2 were expressed [96]. The budding yeast Polo-like kinase
homologue Cdc5 has also been shown to be required for DNA
damage checkpoint silencing in the presence of persisting DSBs
[29]. Moreover, S. cerevisiae cells lacking a wt-CDC5 allele were
unable to silence the activity of the Chk2 homologue Rad53 [97],
indicating that, directly or indirectly, Polo-like kinase may regulate
Chk2 function in that organism. The budding yeast 53BP1/Mdc1
homologue Rad9 has been shown to regulate checkpoint responses
to DNA damage. Similar to 53BP1, Rad9 is activated by the
ATM/ATR homologues Tel1/Mec1 and associates with the Chk2
homologue Rad53 [98–100]. A role for Rad9 as a target for
feedback control to silence checkpoint functioning, however, has
not yet been shown.
In addition to constituting a mechanism for silencing an
activated DNA damage checkpoint, the Cdk1-Plk1-53BP1 feed-
back loop may be a more general means to prevent activation of
the DNA damage checkpoint during mitosis. If a DNA damage–
induced G2-like checkpoint were to become fully functional during
mitosis, DNA lesions encountered during mitotic progression
could result in inactivation of Cdk1/Cyclin B and result in forced
mitotic exit. Such an event would cause the accumulation of 4N-
DNA containing interphase cells, which were recently shown to
have increased tumorigenic potential [101,102]. Hence it can be
expected that cellular mechanisms exist to prevent inappropriate
Cdk1 inactivation during mitosis. Indeed, DNA damage during
mitosis had previously been shown to be unable to delay mitotic
progression or alter Cdk1 activity during mitosis [39,40]. Our
observation that Chk2 cannot be catalytically activated during
mitosis by IR further strengthens this notion.
Immortalized proliferating cells are believed to have increased
replication stress and elevated levels of associated DNA damage.
The DNA damage checkpoint, therefore, was shown to form a
barrier against malignant transformation [8,9]. Feedback mech-
anisms, in which mitotic kinases can silence DNA damage
checkpoints, may thus explain why Plk1 and Aurora A are
frequently overexpressed in cancers and may form a rationale for
including inhibitors of such mitotic kinases during cancer
treatment [103–105].
Materials and Methods
Bioinformatics Analysis of Conserved Phosphorylation
Sites in the DNA Damage Signaling Network
A total of 244 in vivo mapped phosphorylation sites on 33
human DDR-related proteins were manually collected from
Phospho.ELM [42], Phosphosite [43], and a phospho-proteomic
study of Polo Box substrates [44]. The conservation level of these
phosphorylation sites was measured by aligning predicted
orthologues of these proteins in 11 species from the high-coverage
vertebrate branch of Ensembl (release 46; [106]) with the human
seed sequences in which the sites had been mapped by mass
spectrometry and other means. Genomes used in the analysis
included Homo sapiens (human), Bos taurus (cow), Canis familiaris
(dog), Danio rerio (zebrafish), Gallus gallus (chicken), Macaca
mulatta (rhesus monkey), Mus musculus (house mouse), Ornithor-
hynchus anatinus (platypus), Rattus norvegicus (Norway rat),
Tetraodon nigroviridis (fresh water pufferfish), and Xenopus
tropicalis (western clawed frog).
Ortholog mapping was performed as follows: initially the
human DDR sequences and phosphorylation sites were mapped to
their corresponding Ensembl gene entries by sequence compar-
ison. Next, genes orthologous to the DDR genes were retrieved
from Ensembl. Orthologous relationships between human and
other vertebrate genes in Ensembl were inferred from phylogenetic
trees constructed from multiple sequence alignment of CDS
sequences [106]. A detailed description of Ensembl ortholog
detection pipeline in release 46 is available at http://aug2007.
archive.ensembl.org/info/data/compara/homology_method.html.
Finally, each DDR protein sequence and all spliced variants of
its orthologous genes across the 11 species were aligned using
multiple-sequence alignment program MAFFT (v6.240, E-INS-i
option with default parameters) [107].
Cross-species conservation of the human phosphorylation sites
was then computed by evaluating the average number of amino
acid substitutions within a 25t o+5 residue window of the
modified residue (S, T, or Y) across the 11 vertebrate genomes
from the sequence alignments using Perl scripting. SRT and
TRS transitions of the central phosphoresidue were permitted,
but S/TRY transitions were not. The conservation level for each
phosphorylation site is reported as the average across the 11
or presence of Plk1 inhibitor (black bars). Cells were harvested at 1, 8, and 16 h after paclitaxel addition, and phospho-Histone H3 content was
determined by flow cytometry. (D) U2OS were infected with wt- or S376A-EGFP-m53BP1 and, 48 h later, irradiated with 3Gy IR. Cells were harvested
12 h later, stained with anti-c-H2AX, and analyzed by FACS. Blue lines indicate c-H2AX levels from cells infected with retroviruses encoding wt-EGFP-
m53BP1 while red lines indicate c-H2AX levels from cells infected with retroviruses encoding S376A-EGFP-m53BP1. GFP-positive (infected) cells and
GFP-negative (uninfected) cells are plotted separately. (E) U2OS cells were infected with retroviruses encoding wt-EGFP-m53BP1 or S376A-EGFP-
m53BP1 and treated with paclitaxel for indicated time periods. Percentages of phospho-Histone H3-positivity within the GFP-positive cell population
were analyzed by FACS. (F) U2OS cells were infected with retroviruses encoding wt-EGFP-m53BP1 or the S376A-EGFP-m53BP1 mutant and, 48 h later,
irradiated with 3 Gy. Thirty minutes after irradiation, paclitaxel was added and the percentages of phospho-Histone H3-positive cells within the GFP-
expressing cell populations were determined by flow cytometry at the indicated times. Mean values and SEM from three independent experiments
are shown.
doi:10.1371/journal.pbio.1000287.g006
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window, if the corresponding S/T is conserved.
Information about which of the 244 in vivo mapped
phosphorylation sites were phosphorylated by the specific kinases
ATM/ATR, Cdk1/2, Chk1/2, and Plk1 was collected from
Phospho.ELM [42] and Phosphosite [43], along with whether
phosphorylation at that site was known to create a binding site for
the PBD of Plk1 [44]. In cases where multiple kinases are known
to phosphorylate a single site, all of this information was retained
and displayed. For sites where the upstream kinase was not
experimentally known, we predicted the likely kinase responsible
for phosphorylation at that site by computational analysis using
the programs NetworKIN [45,47] and NetPhorest [46].
Antibodies, Plasmids, and Reagents
Rabbit anti-53BP1 (304-A1) was from Novus Biologicals. Mouse
anti-c-H2AX (pS139, #05-636), rabbit anti-HistoneH3 pS10
(#06570), rabbit anti-Chk2 (#2662), rabbit anti-Chk2-pT68
(#2661), rabbit anti-53BP1-pS1778 (#2675), mouse anti-MPM2
(#05-368), and rabbit anti-Plk1 (#06-831) were purchased from
Upstate. An additional rabbit anti-Chk2 antibody (#BL1432) was
purchased from Bethyl Laboratories. Rabbit anti-Plk1 for
immunoprecipitation was a kind gift from Dr. Rene ´ Medema.
Mouse anti-b-actin (A5441) was from Sigma. Mouse anti-Cyclin
B1 (GNS1, sc-245), rabbit anti-GFP (sc-8334), and rabbit non-
specific IgG (sc-2025) were from Santa Cruz Biotechnology.
Mouse anti-GFP (clones 7.1 and 13.1) was from Roche. Rabbit
Figure 7. Inactivation of Chk2 by Plk1. (A) U2OS cells were treated with nocodazole in the absence or presence of the Plk1-inhibitor BI 2536 for
16 h. Mitotic cells were collected using gentle shake-off and subsequently irradiated (5Gy) as indicated. Chk2 was immunoprecipitated and kinase
activity was assessed by incorporation of [
32P]-c-ATP into the optimal substrate peptide (‘‘Chk2-tide’’) in an in vitro kinase assay. Means and standard
deviations from three independent experiments are shown. (B) A recombinant GST fusion of full-length Chk2 was incubated with Plk1 kinase domain
in the presence of [
32P]-c-ATP. Samples were analyzed by SDS-PAGE and imaged by Coomassie staining (top) and autoradiography (bottom). (C) 293T
cells were transfected with FLAG-Chk2. Twenty-four hours after transfection, cells were treated with paclitaxel in combination with DMSO or in
combination with Plk1 for 8 h. FLAG-Chk2 was subsequently immunoprecipitated from lysates, analyzed by SDS page, and imaged by staining. (D)
Following in vitro phosphorylation by Plk1 as in panel B, the kinase activity of Chk2 was measured by the incorporation of [
32P]-c-ATP into the
optimal substrate peptide (‘‘Chk2-tide’’). A reaction containing Plk1 but lacking Chk2 is shown as a control. Data are normalized to the amount of
Chk2tide phosphorylation observed for Chk2 alone. (E) The Chk2 FHA domain, prior to or following phosphorylation by Plk1 in the presence of [
32P]-
c-ATP, was incubated with a biotinylated phosphothreonine peptide library bound to streptavidin beads. Input (10%) and bead-bound material was
analyzed by SDS-PAGE and immunoblotting with anti-GST, or by autoradiography to assess phosphorylation state. (F) Schematic representation of
human Chk2. Evolutionarily conserved phosphorylation sites in the FHA domain that match the optimal Plk1 consensus motif and were identified
following in vitro phosphorylation by mass spectrometry are indicated. (G) A structural basis for Plk1-mediated inactivation of Chk2. Left panel: The
near full-length Chk2 dimer is shown in ribbons representation, with monomers colored green and cyan. Residues phosphorylated by Plk1 are shown
in space filling representation. Right panel: The isolated Chk2 FHA domain:phosphopeptide complex, shown in the same orientation as the boxed
region in the left panel. The phospho-threonine peptide ligand and the modeled side chain of phospho-Ser-164 are shown in stick representation
with phosphates colored purple. (H) U2OS cells were transfected with the indicated pIRES2-Chk2 plasmids co-expressing GFP. Cells were fixed and
stained with PI and an anti-phospho-HistoneH3 antibody. GFP-positive cells were gated and the corresponding DNA profiles and percentages of
phospho-HistoneH3-positive cells are indicated on the lower panels. (I) U2OS cells were treated as in panel H. Cells were left untreated for 48 h or
irradiated (3Gy) and subsequently treated with paclitaxel for 24 h. Percentage of GFP-positive cells that are phosphoHistoneH3 positive at 24 h after
irradiation are shown. Averages and standard errors of two experiments are shown.
doi:10.1371/journal.pbio.1000287.g007
Figure 8. A model for mitotic checkpoint inactivation. One model for checkpoint inactivation at the G2-M transition. Left panel: DNA lesions
promote the formation of protein complexes, including 53BP1 and Chk2, that mediate checkpoint function and promote DNA repair. Green symbols
indicate active kinases. Right panel: (1) To terminate the ATM-Chk2 branch of the G2/M checkpoint, CyclinB/Cdk1 phosphorylates DNA damage
signaling proteins, including 53BP1. (2) Cdk1 phosphorylation of 53BP1 creates a Plk1 PBD docking site, leading to Plk1 recruitment, phosphorylation
of checkpoint components, and inactivation of the Chk2 FHA domain. (3) These combined phosphorylation events by mitotic kinases drive cell cycle
reentry and prevent further DNA damage checkpoint activation during mitosis.
doi:10.1371/journal.pbio.1000287.g008
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peptide Pro-Phe-Iso-Val-Pro-Ser-pSer-Pro-Thr-Glu-Gln-Glu-Gly-
Arg-Tyr and purified by Cell Signaling Technologies. Radiola-
belled [
32P]-c-ATP (3,000 Ci/mmol) was purchased from
Amersham/GE Healthcare. Plk1 inhibitor (BI 2536) was synthe-
sized following the procedure described by Munzert et al. [108].
All other reagents and chemicals were from Sigma unless
otherwise indicated.
The pEGFP-m53BP1 expressing murine GFP-Tagged 53BP1
was kindly provided by Dr. Yasuhisa Adachi. The Nhe1-Apa1
fragment of pEGFP-m53BP1 was cloned in the retroviral plasmid
pLNCX2 (Clontech) containing a synthetic linker to generate
pLNCX2-GFP-m53BP1. PCR-based mutagenesis was used to
create pLNCX2-GFP-m53BP1-317A, m53BP1-330A, m53BP1-
376A, m53BP1-922A, m53BP1-1103A, and m53BP1-1620A. All
plasmid constructs were verified by automated sequencing.
pLNCX2-GFP-m53BP1D196–439 was created by a nested PCR
on two m53BP1 PCR fragments surrounding the deletion. The
resulting 53BP1 fragment containing the deletion was used to
replace wt-m53BP1 in pLNCX2-GFP-m53BP1. Full-length hu-
man Chk2 was cloned from pGEX6P2-Chk2 and subcloned into
the Nhe1-EcoR1 sites of pIRES2-GFP (Clontech). Serine/
Threonine to Alanine mutations at positions 164, 168, 205, and
210 were obtained by side directed mutagenesis and validated
using automated sequencing. Full-length FLAG-tagged Chk2 was
a kind gift from Dr. Domenico Delia. VSV-G pseudotyped
retroviruses were prepared according to standard techniques. In
brief, HEK293T packaging cells were transfected with the
pLNCX-2 and the packaging plasmids pMDg/p and pMDg in a
4:3:1 ratio. Virus-containing supernatant was harvested at 24 and
48 h after transfection, filtered through a 0.45 mM syringe filter,
and used to infect U2OS osteosarcoma target cells. A plasmid
encoding the PBD of Plk1 (aa. 326–603) fused to GST was
described previously [50].
Cell Culture
U2OS osteosarcoma cells were maintained in Dulbecco’s
Modified Eagle medium, supplemented with 10% fetal calf serum,
100 units/ml penicillin, and 100 mg/ml streptomycin. To obtain
mitotic cell populations, cells were incubated with paclitaxel
(1 mg/ml) or nocodazole (250 ng/ml, Sigma). Where indicated,
cells were harvested by mitotic shake-off. Where indicated, DNA
damage was induced using a gamma-cell 40 irradiator equipped
with a
137Cesium source for indicated doses. Alternatively, cells
were incubated with doxorubicin (0.5 mM) for 1 h.
RNA Interference
Human breast cancer cell line MCF7 or human osteosarcoma
U2OS cells were retrovirally infected with control pRetrosuper or
pRetrosuper-53BP1 (53BP1-targeting sequence #1, 59-GA-
TACTGCCTCATCACAGT-39; 53BP1-targeting sequence #2
59-GAACGAGGAGACGGTAATA-39) for three consecutive
12 h periods [61]. Infected cells were selected with 2 mg/ml
puromycin. pRS-53BP1-infected MCF7 cells were subsequently
treated with 4 mM nutlin-3 to select for cells with a functional
53BP1 knockdown [61]. The statistical analysis of colony numbers,
S-phase content, and phospho-HistoneH3 content in control-
infected or pRS-53BP1-infected MCF-7 cells was done using the
unpaired t test. Two-tailed p values were calculated using
GraphPath software.
Protein Purification
The Plk1 kinase domain (residues 38–346) was made as a His6-
tagged construct in Escherichia coli (E. coli) Rosetta cells (Novagen)
and purified by Ni-NTA chromatography followed by gel filtration
on a Superose-12 column. Recombinant full-length GST-Chk2
and a GST-Chk2 FHA domain (amino acids 1–219) fusion were
expressed and purified from E. coli. In brief, full-length Chk2 was
cloned into pGEX-6P1 (GE Healthcare) and transformed into
BL21 (DE3) cells. Cells were grown at 37uC to an OD600 of 0.6
and the culture temperature was reduced to 18uC for 30 min
before a final concentration of 0.3 mM IPTG was added for
overnight expression. Cells were pelleted and washed with
MTPBS (16 mM Na2HPO4, 4 mM NaH2PO4, 150 mM NaCl,
pH 7.3) and lysed by sonication in the same buffer with the
addition of benzonase. The lysate was clarified by centrifugation,
and the GST-Chk2 fusion protein was captured on glutathione 4B
resin. After washing with 30 column volumes of phosphate-
buffered saline (PBS), Chk2 was cleaved off the GST tag on the
resin with 3C protease at 4uC overnight. The eluted full-length
Chk2 was further purified by anion exchange on a Resource Q
column (GE Healthcare) equilibrated with 20 mM Tris pH 8.0,
50 mM NaCl, 0.5 mM TCEP, and developed with 20 mM Tris
pH8, 1 M NaCl, and 0.5 mM TCEP. Peak fractions containing
full-length Chk2 were pooled and further purified with a Superdex
S200 gel filtration column (GE Healthcare).
The GST-Chk2 FHA domain cloned into pGex-4T1 was
transfected into BL21(DE3) cells, grown to an OD600 of 0.8, and
induced with 1 mM IPTG at 37uC for 6 h. Cells were lysed in
PBS containing 1 mM DTT and a mixture of protease inhibitors
and disrupted by sonication. Benzonase (Novagen) was added at
room temperature for 30 min and the lysate cleared via
centrifugation. Roughly 500 mL of PBS-equilibrated GSH beads
were added to the lysate and incubated at 4uC with rocking
overnight. Non-bound material was aspirated off followed by
4610 mL washes with PBS containing 0.2% NP-40 and 1 mM
DTT, and the GST-Chk2 FHA domain eluted off the beads by
incubation in 2.5 mL of elution buffer (20 mM HEPES pH 7.2,
40 mM glutathione, and 1 mM DTT; EB+G) at 4uC overnight.
The purified GST-Chk2 FHA domain was dialyzed against
elution buffer lacking 40 mM glutathione (EB) using a Slide-A-
Lyzer (Pierce) dialysis cassette with a molecular weight cut-off of
6–8 kDa at 4uC with three buffer exchanges. Purity was assessed
by SDS-PAGE and the protein concentration determined by
absorbance at A280 using an extinction coefficient of
71,780 M
21 cm
21.
Chk2 FHA Domain-Phospho-Peptide Binding Assay
Streptavidin beads (Pierce, 75 pmol/mL gel) were incubated
with a 5-fold molar excess (relative to binding capacity) of a
biotinylated phosphothreonine-oriented peptide library (B-4pT5;
biotin-Gly-AHA-Gly-AHA-Met-Ala-X-X-X-X-pThr-X-X-X-X-X-
Ala-Tyr-Lys-Lys-Lys-NH2, where X indicates a equimolar de-
generate mixture of all amino acids except Cys, and pThr
denotes phosphothreonine) in 50 mM Tris pH 7.5, 150 mM
NaCl, 0.5% NP-40, and 1 mM EDTA for 30 min at 4uC. Beads
were washed five times with the same buffer to remove unbound
peptides and then 20 mL of the bead-immobilized library was
incubated with 10 mg of GST-Chk2 FHA domain prior to or
following in vitro phosphorylation of the FHA domain by Plk1
kinase in the presence of [
32P]-cATP. After a 60 min incubation,
the beads were washed five times with 50 mM Tris pH 7.5,
150 mM NaCl, 0.5% NP-40, and 1 mM EDTA. Bead-bound
protein was released by addition of SDS sample buffer with
heating to 95uC and resolved by SDS-PAGE on 10% denaturing
gels. Gels were analyzed by autoradiography using a phosphorsc-
reen and a Typhoon variable mode imager (GE Healthcare, or
transferred to PVDF membrane and immunoblotted using an
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GST-FHA domain).
Immunofluorescence
U2OS cells were seeded on glass cover slips and treated as
indicated. After treatment, cells were fixed in 3.8% formaldehyde
in PBS for 15 min at room temperature. Subsequently, cells were
permeabilized with 0.1% TritonX100 in PBS for 5 min. After
extensive washing, cells were blocked and stained in PBS-0.05%
Tween20 and mounted on slides. Images were acquired on a Zeiss
Axioplan-2 inverted microscope, equipped with a Hamamatsu
Orca-ER digital camera using OpenLab software.
Immunoprecipitation, In Vitro Phosphorylation, and
Kinase Assays
After the indicated treatments, U2OS cells were lysed in lysis
buffer (1% TritonX-100, 50 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 50 mM beta-glycerophosphate, 10 mM sodium pyrophos-
phate, 30 mM NaF, 1 mM benzamidine, 2 mM EGTA, 100 mM
NaVO4, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl
fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mg/ml
pepstatin, and 1 mg/ml microcystin-LR) for 15 min at 4uC and
cleared by high speed centrifugation. Protein concentrations were
measured using the bicinchoninic acid assay (Pierce). 53BP1 was
immunoprecipitated from 500 mg of clarified cell lysate using 3 mg
of anti-53BP1 antibody and 50 mls of Protein-A-conjugated
agarose beads (50% slurry) for 16 h. Immunoprecipitations were
extensively washed and analyzed by SDS-Page and Western
blotting. Alternatively, immunoprecipitations were subjected to in
vitro phosphorylation by resuspension in kinase buffer (50 mM
Tris-HCL pH7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT,
2 mM dithiothreitol, 0.01% BRIJ35, and 150 mM NaCl2),
followed by addition of 25 mM unlabelled ATP, 10 mCi of [
32P]-
c-ATP, and recombinant Cyclin A-Cdk2, Cyclin B-Cdk1, or Plk1
for 30 min. Kinase reactions were analyzed by SDS-page and
autoradiography.
IP/kinase assays for Chk2 activity were performed as generally
described [109] using lysates from either interphase cells or from
mitotic cells generated by treating U2OS cells with 0.25 mg/ml
nocodazole for 16 h followed by harvesting of the mitotitc non-
adherent cells by gentle shaking. In brief, Protein A microtiter
strips (Pierce) were coated overnight with 1.0 mg of anti-Chk2
antibody (Bethyl) or non-specific rabbit IgG per well and washed
three times with blocking buffer (1% bovine serum albumin in
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.05% Triton X-100).
Cell lysates (100 mgs) were placed in each antibody-coated well,
incubated for 3 h, then washed twice with wash buffer (50 mM
Tris-HCl (pH 7.5), 150 mM NaCl) and twice with kinase wash
buffer (20 mM Tris-HCl (pH 7.5), 15 mM MgCl2, 5 mM beta-
glycerophosphate, 1 mM EGTA, 0.2 mM Na3VO4, 0.2 mM
DTT). Kinase reactions were performed in a total volume of
60 ml containing 20 mM Tris-HCl (pH 7.5), 15 mM MgCl2,
5m M b-glycerophosphate, 1 mM EGTA, 0.2 mM Na3VO4,
0.2 mM DTT, 0.4 mM protein kinase A inhibitor, 4 mM protein
kinase C inhibitor, 4 mM calmidazolium, 25 mM ATP, 10 mCi
[
32P]-c-ATP, and 10 mM of Chk2tide substrate. Reactions were
incubated for 60 min at 37uC, then terminated by addition of
60 ml of 20 mM EDTA. Forty ml of the terminated reaction
mixture was transferred to a phosphocellulose filter plate
(Millipore, Bedford, MA) containing 100 ml, 75 mM H3PO4,
and mixed. The reaction contents were vacuum-filtered and
washed five times with 75 mM H3PO4 and three times with 70%
ethanol. Scintillation counting was performed using a Microbeta
TRILUX luminescence counter.
In vitro phosphorylation of recombinant Chk2 or the Chk2
FHA domain by Plk1 was performed by incubating 3–10 mgs of
the substrate proteins with Plk1 kinase domain in 50 mM Tris
pH 7.5 containing 150 mM NaCl, 10 mM MgCl2, 100 mg/ml
bovine serum albumen, 5 mM DTT, and 100–500 mM unlabelled
ATP, in the presence or absence of 10–20 mCi [
32P]-c-ATP, for
60–120 min at 30uC. Kinase assays of recombinant Chk2 before
or after Plk1 phosphorylation were performed in the above buffer
containing 1 mM DTT, 20 mCi [
32P]-c-ATP, and 50 mM
Chk2tide in a final reaction volume of 50 mla t3 0 uC for 60 min.
Samples were quenched with an equal volume of 0.05% H3PO4,
and 5 ml of the reaction spotted onto P81 paper, air dried, washed
extensively with 0.05% H3PO4, and analyzed by scintillation
counting.
Identification of Plk1 phosphorylation sites in the Chk2 FHA
domain following in vitro phosphorylation was performed by
separating the reaction products by SDS-PAGE. Gel slices
containing Chk2 were excised, alkylated with iodoacetamide,
and digested with trypsin. Peptides were resolved by nano-flow
reversed phase liquid chromatography (Agilent 1100, Palo Alto,
CA) and analyzed with a LTQ-Orbitrap equipped with a
nanoelectrospray ionization source (Thermo, Bremen, Germany).
Peptide and protein identification was analyzed using the
Spectrum Mill MS Proteomics Workbench software (Agilent).
For the in vivo mobility shift analysis of Chk2, 293T cells were
transfected with FLAG-tagged full-length hChk2. Twenty-four h
after transfection, cells were treated with paclitaxel in combination
with DMSO or in combination with Plk1 inhibitor for 8 h. Cell
lysates were cleared by centrifugation and mixed with M2 FLAG
resin for overnight immunoprecipitation. After washing, samples
were analyzed by SDS-PAGE.
Flow Cytometry
Cells were harvested with Trypsin/EDTA, washed with PBS,
and subsequently fixed in ice-cold 70% ethanol for 4–16 h. After
washing, cells were stained with anti-phospho-Histone H3 (1:200)
or anti-phospho-c-H2AX (1:100) in PBS-0.05% Tween20 and
counterstained with Alexa647-conjugated secondary antibodies in
PBS-0.05% Tween20. Cells were treated with Propidium Iodide/
RNAse and analyzed on a Becton Dickinson FACScalibur using
Cellquest software. A minimum of 10,000 events were counted.
Supporting Information
Figure S1 (A) U2OS cells were left untreated or were treated
with nocodazole for 16 h. Total cell lysates were immunoblotted
using indicated antibodies (left panel). In parallel, cell lysates were
used for anti-Plk1 or control (IgG) immunoprecipitations (right
panel). Immunoprecipitations were washed extensively and
immunoblotted for Plk1 and 53BP1. (B) Co-localization of
53BP1 with cH2AX in interphase but not mitosis. U2OS cells
were left untreated or subjected to 3 Gy of ionizing radiation.
Thirty minutes after irradiation, cells were fixed and immuno-
stained using murine anti-c-H2AX/anti-mouse-Alexa568 and
rabbit anti-53BP1/anti-rabbit-Alexa488. Left panel: The number
of nuclear foci per cell was counted from 30 interphase and 30
mitotic cells. Averages and standard error of the mean (SEM) are
indicated. Middle panel: c-H2AX foci from irradiated interphase
and mitotic cells were analyzed for their co-localization with
53BP1 by visual inspection. One hundred and forty-six distinct c-
H2AX foci from 20 interphase cells and 76 discrete c-H2AX foci
from 30 mitotic cells from the left panel were analyzed. Co-
localization was defined as any overlap between the two signals.
The percentages of c-H2AX foci with an overlapping 53BP1
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interphase cells in the left panel were analyzed for their co-
localization with cH2AX as in the middle panel. One hundred
and thirty-six distinct 53BP1 foci from 20 interphase cells were
analyzed. During mitosis essentially no distinct 53BP1 foci were
observed; thus mitotic cells were not included in this analysis. (C)
U2OS cells were treated with DMSO or with the Plk1 inhibitor BI
2536 for 6 h. Anti-53BP1 and anti-c-H2AX were used to stain
DNA damage-induced foci. Average numbers of 53BP1 foci from
25 cells are indicated in the bar graph and representative cells with
c-H2AX staining are indicated. As a reference, U2OS cells were
harvested 1 h after 5 Gy ionizing irradiation.
Found at: doi:10.1371/journal.pbio.1000287.s001 (1.19 MB EPS)
Figure S2 (A) Recombinant GST-Chk2 (1–219) was incubated
with recombinant Plk1. GST-Chkl2 (1–219) was separated using
SDS-page and subsequently purified and trypsin-digested. Phos-
phorylation of peptides was analyzed using LC-MS/MS. Phos-
phorylated serine and threonine residues and their relative position
in a schematic Chk2 representation are indicated. (B) List of
identified phosphorylated peptides. Observation frequency and
observed phosphorylated residues are indicated. (C) Selection of
phosphorylation sites. Identified phosphorylation sites that were
observed at least twice and that showed an evolutionary conserved
phosphorylation sites as well as a evolutionary conserved Plk1
phosphorylation consensus motif ([Asp/Glu][X][Ser/Thr]) are
selected and depicted.
Found at: doi:10.1371/journal.pbio.1000287.s002 (0.69 MB TIF)
Table S1 For each indicated phospho-residue (column A), the
conservation of the 25/+5 motif is indicated for 11 species
(human-H.sap; rhesus monkey-M.mul; mouse-M.mus; rat-R.nor;
cow-B.tau; dog-C.fam; platypus-O.ana; chicken-G.gal; African
clawed frog-X.tro; zebrafish-D.rer; pufferfish-D.nig). Conservation
is calculated and is indicated on a 0–1 scale. Full conservation of
the 25/+5 motif results in a score of 1; absence of conservation or
absence of the conservation of the phospho-residue results in a
score of 0. ‘‘NA’’ indicates that sequence information for this
species is unavailable. ‘‘Incomplete’’ indicates that gaps exist in the
sequence data and that information for a specific residue could not
be retrieved. Motif conservation (column ‘‘M’’) indicates the mean
conservation of the 25/+5 motif over all 11 species. Phosphosite
conservation (column ‘‘N’’) indicates the conservation rate of the
actual phospho-residue.
Found at: doi:10.1371/journal.pbio.1000287.s003 (0.07 MB XLS)
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